Oppenheimer analyst Jay Olson reiterated an Outperform rating and $300.00 price target on Biogen (NASDAQ: BIIB).The analyst commented: "BIIB delivered ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments